Is your go-to-market built to scale — or running on heroics?
A 10-minute self-assessment. Eight questions, no form, no follow-up unless you want one.
In 2026 the bar for healthy growth has moved. Efficient growth — not growth at any cost — is what the market rewards, and the companies that scale predictably are the ones whose GTM is a system rather than a set of heroics. Run through the eight areas below and score each one. The pattern matters more than any single answer.
A warning before you start
The hard part isn’t the questions — it’s marking yourself fairly. Most leaders score a shade greener than their team would, so if you’re torn between Amber and Green, it’s almost certainly Amber.
ICP & positioning clarity
Ask yourself: Could everyone on your leadership team explain — in the same words —what you sell, what problem you solve for customers and who you sell to ?
Healthy
A sharp, evidence-based ICP that sales, marketing and CS all sell to; clear reasons you win and lose.
Getting there
Most people tell a similar story, but the emphasis drifts and you still take the odd poor-fit deal you later regret.
Warning Sign
“We can sell to anyone”; win/loss reasons are anecdotal; reps chasing poor-fit deals that clog the funnel.
Pipeline coverage & quality
Ask yourself: Do you have enough qualified pipeline to hit the next two quarters — and do you trust that it’s real?
Healthy
3x+ coverage of genuinely qualified opportunity, built on a repeatable demand engine — not a handful of hero deals.
Getting there
Coverage holds in good quarters but swings; the demand engine works without being predictable enough to bank on.
Warning Sign
Coverage looks fine on paper but a few large, founder-sourced deals are holding it up; thin or unpredictable top of funnel.
Qualification & deal discipline
Ask yourself: If you pulled five open deals at random, could the rep clearly articulate the pain they are solving for the customer and their plan to meet the economic buyer?
Healthy
A common qualification language (e.g. MEDDPICC) used consistently; deals advance on evidence, not optimism.
Getting there
Your best reps qualify well, but it’s applied unevenly across the team and slips when the quarter gets tight.
Warning Sign
Deals slip late and “go dark” at procurement; forecasts move because a champion went quiet, not because anything changed.
Forecast accuracy & predictability
Ask yourself: Over the last four quarters, how close was your start-of-quarter forecast to the actual result?
Healthy
Forecast lands within a tight band quarter after quarter; the board is rarely surprised.
Getting there
Usually close, but the odd quarter still surprises you — you trust the number more some quarters than others.
Warning Sign
Regular swings of 15%+; the dangerous misses are the ones nobody saw coming until late in the quarter.
Sales leadership & operating rhythm
Ask yourself: Is there a weekly cadence — pipeline, deal reviews, a shared scorecard — that the whole revenue team actually runs to?
Healthy
A disciplined operating rhythm your sales leader owns; clear ownership, clear numbers, no theatre.
Getting there
A cadence exists but isn’t always held; reviews happen without consistently changing what reps do next.
Warning Sign
Reviews are ad hoc or status-only; a capable leader handed a number without the rhythm or support to deliver it.
Enablement, ramp & consistency
Ask yourself: If your two best reps left tomorrow, would the rest of the team still hit the number?
Healthy
Performance is spread across the team, not riding on a couple of stars; new hires ramp quickly on a clear playbook, and coaching makes good habits stick after the training room.
Getting there
The middle of the team is improving but still leans on your stars, and ramp is shortening more slowly than you’d like.
Warning Sign
The number depends on one or two people; new hires take far too long to get going; methodology gets talked about but you don’t see it in real deals
Retention & expansion (NRR)
Ask yourself: Is net revenue retention above 100%, and is expansion pulling its weight against net-new?
Healthy
NRR comfortably above 100%; CS measured on revenue, with a clean sales-to-CS handover and a real expansion motion.
Getting there
NRR is hovering around 100%; expansion happens, but more by goodwill than by a deliberate, measured motion.
Warning Sign
New logos are masking churn; CS is a support cost centre; expansion happens by luck, not by design.
Repeatability & founder-dependence
Ask yourself: If you stepped out of every deal for a quarter, what would happen to the number?
Healthy
The engine runs without the CEO/founder in the room; the motion is documented, taught and measured.
Getting there
The team runs most deals, but the big or complex ones still pull you in, and some of the motion still lives in heads.
Warning Sign
The biggest deals still need you; the GTM lives in people’s heads — which investors read as concentration risk.
How to read your score
Mostly Green: you have a system. The work is sharpening and protecting it as you scale.
A cluster of Ambers: you’re at the founder-to-scale transition. This is exactly where most companies stall — and where a focused intervention pays back fastest.
Two or more Reds: growth is being constrained by something fixable, and it’s probably costing you deals and valuation right now.
One caveat worth holding onto: this tells you where to look, not what’s actually wrong. A shaky forecast score doesn’t tell you whether the cause is qualification, coverage or leadership rhythm — and the fix is completely different in each case. That’s the difference between a self-check and a diagnosis.
Want the full picture, not just the headline?
This check tells you where to look. Our GTM Audit tells you exactly what’s wrong, what it’s costing you, and what to fix first — a complete operator’s diagnosis in two to three weeks. It’s the lowest-risk way to turn a hunch into a plan.